Marko Z. Vatamaniuk
University of Pennsylvania
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Marko Z. Vatamaniuk.
Genes & Development | 2008
Nan Gao; John LeLay; Marko Z. Vatamaniuk; Sebastian Rieck; Joshua R. Friedman; Klaus H. Kaestner
The onset of pancreas development in the foregut endoderm is marked by activation of the homeobox gene Pdx1 (IPF1). Pdx1 is essential for the expansion of the pancreatic primordium and the development of endocrine islets. The control of Pdx1 expression has been only partially elucidated. We demonstrate here that the winged-helix transcription factors Foxa1 and Foxa2 co-occupy multiple regulatory domains in the Pdx1 gene. Compound conditional ablation of both Foxa1 and Foxa2 in the pancreatic primordium results in complete loss of Pdx1 expression and severe pancreatic hypoplasia. Mutant mice exhibit hyperglycemia with severely disrupted acinar and islet development, and die shortly after birth. Assessment of developmental markers in the mutant pancreas revealed a failure in the expansion of the pancreatic anlage, a blockage of exocrine and endocrine cell differentiation, and an arrest at the primitive duct stage. Comparing their relative developmental activity, we find that Foxa2 is the major regulator in promoting pancreas development and cell differentiation. Using chromatin immunoprecipitations (ChIP) and ChIP sequencing (ChIPSeq) of fetal pancreas and islet chromatin, we demonstrate that Foxa1 and Foxa2 predominantly occupy a distal enhancer at -6.4 kb relative to the transcriptional start site in the Pdx1 gene. In addition, occupancy of the well-characterized proximal Pdx1 enhancer by Foxa1 and Foxa2 is developmental stage-dependent. Thus, the regulation of Pdx1 expression by Foxa1 and Foxa2 is a key early event controlling the expansion and differentiation of the pancreatic primordia.
Journal of Clinical Investigation | 2005
Rana K. Gupta; Marko Z. Vatamaniuk; Catherine S. Lee; Reed C. Flaschen; James T. Fulmer; Franz M. Matschinsky; Stephen A. Duncan; Klaus H. Kaestner
Mutations in the gene encoding hepatocyte nuclear factor-4alpha (HNF-4alpha) result in maturity-onset diabetes of the young (MODY). To determine the contribution of HNF-4alpha to the maintenance of glucose homeostasis by the beta cell in vivo, we derived a conditional knockout of HNF-4alpha using the Cre-loxP system. Surprisingly, deletion of HNF-4alpha in beta cells resulted in hyperinsulinemia in fasted and fed mice but paradoxically also in impaired glucose tolerance. Islet perifusion and calcium-imaging studies showed abnormal responses of the mutant beta cells to stimulation by glucose and sulfonylureas. These phenotypes can be explained in part by a 60% reduction in expression of the potassium channel subunit Kir6.2. We demonstrate using cotransfection assays that the Kir6.2 gene is a transcriptional target of HNF-4alpha. Our data provide genetic evidence that HNF-4alpha is required in the pancreatic beta cell for regulation of the pathway of insulin secretion dependent on the ATP-dependent potassium channel.
Journal of Clinical Investigation | 2004
Kristen A. Lantz; Marko Z. Vatamaniuk; John Brestelli; Joshua R. Friedman; Franz M. Matschinsky; Klaus H. Kaestner
The regulation of insulin secretion by pancreatic beta cells is perturbed in several diseases, including adult-onset (type 2) diabetes and persistent hyperinsulinemic hypoglycemia of infancy (PHHI). The first mouse model for PHHI has a conditional deletion of the gene encoding the winged-helix transcription factor Foxa2 (Forkhead box a2, formerly Hepatocyte nuclear factor 3beta) in pancreatic beta cells. Using isolated islets, we found that Foxa2 deficiency resulted in excessive insulin release in response to amino acids and complete loss of glucose-stimulated insulin secretion. Most PHHI cases are associated with mutations in SUR1 (Sulfonylurea receptor 1) or KIR6.2 (Inward rectifier K(+) channel member 6.2), which encode the subunits of the ATP-sensitive K(+) channel, and RNA in situ hybridization of mutant mouse islets revealed that expression of both genes is Foxa2 dependent. We utilized expression profiling to identify additional targets of Foxa2. Strikingly, one of these genes, Hadhsc, encodes short-chain L-3-hydroxyacyl-coenzyme A dehydrogenase, deficiency of which has been shown to cause PHHI in humans. Hadhsc is a direct target of Foxa2, as demonstrated by cotransfection as well as in vivo chromatin immunoprecipitation experiments using isolated islets. Thus, we have established Foxa2 as an essential activator of genes that function in multiple pathways governing insulin secretion.
Human Gene Therapy | 2004
Gary P. Kobinger; Shaoping Deng; Jean-Pierre Louboutin; Marko Z. Vatamaniuk; Franz M. Matschinsky; James F. Markmann; Steven E. Raper; James M. Wilson
Type I diabetes is caused by an autoimmune-mediated elimination of insulin-secreting pancreatic islets. Genetic modification of islets offers a powerful molecular tool for improving our understanding of islet biology. Moreover, efficient genetic engineering of islets could allow for evaluation of new strategies aimed at preventing islet destruction. The present study evaluated the ability of a human immunodeficiency virus (HIV)-based lentiviral vector pseudotyped with various viral envelopes to target human islets ex vivo, with the goal of improving efficiency while minimizing toxicity. Transfer of the enhanced green fluorescent protein reporter gene in human islets was first evaluated with an HIV-based vector pseudotyped with the vesicular stomatitis virus (VSV), murine leukemia virus, Ebola, rabies, Mokola, or lymphocytic choriomeningitis virus (LCMV) envelope glycoprotein to optimize transduction efficiency. Results indicated that LCMV-pseudotyped vector transduced insulin-secreting beta cells with the highest efficiency. Moreover, toxicity associated with transduction of islets was found to be lower with LCMV-pseudotyped vector than with VSV-G-pseudotyped vector, the second most efficient vector for islet transduction. Overall, our study describes an improved methodology for achieving safe and efficient gene transfer into cells of human islets.
Diabetes | 2006
Marko Z. Vatamaniuk; Rana K. Gupta; Kristen A. Lantz; Nicolai M. Doliba; Franz M. Matschinsky; Klaus H. Kaestner
Foxa1 (formerly hepatic nuclear factor 3α) belongs to the family of Foxa genes that are expressed in early development and takes part in the differentiation of endoderm-derived organs and the regulation of glucose homeostasis. Foxa1−/− pups are growth retarded and hypoglycemic but glucose intolerant in response to an intraperitoneal glucose challenge. However, the mechanism of glucose intolerance in this model has not been investigated. Here, we show that Foxa1−/− islets exhibit decreased glucose-stimulated insulin release in islet perifusion experiments and have significantly reduced pancreatic insulin and glucagon content. Moreover, Foxa1−/− β-cells exhibit attenuated calcium influx in response to glucose and glyburide, suggesting an insulin secretion defect either at the level or upstream of the ATP-sensitive K+ channel. Intracellular ATP levels after incubation with 10 mmol/l glucose were about 2.5 times lower in Foxa1−/− islets compared with controls. This diminished ATP synthesis could be explained by increased expression of the mitochondrial uncoupling protein uncoupling protein 2 (UCP2) in Foxa1-deficient islets, resulting in partially uncoupled mitochondria. Chromatin immunoprecipitation assays indicate that UCP2 is a direct transcriptional target of Foxa1 in vivo. Thus, we have identified a novel function for Foxa1 in the regulation of oxidative phosphorylation in pancreatic β-cells.
Diabetes | 2004
Shaoping Deng; Marko Z. Vatamaniuk; Xiaolun Huang; Nicolai M. Doliba; Moh Moh Lian; Adam Frank; Ergun Velidedeoglu; Niraj M. Desai; Brigitte Koeberlein; Bryan A. Wolf; Clyde F. Barker; Ali Naji; Franz M. Matschinsky; James F. Markmann
Genes & Development | 2001
Newman J. Sund; Marko Z. Vatamaniuk; Melissa Casey; Siew-Lan Ang; Mark A. Magnuson; Doris A. Stoffers; Franz M. Matschinsky; Klaus H. Kaestner
Diabetes | 2002
Catherine S. Lee; Newman J. Sund; Marko Z. Vatamaniuk; Franz M. Matschinsky; Doris A. Stoffers; Klaus H. Kaestner
American Journal of Physiology-endocrinology and Metabolism | 2004
Nicolai M. Doliba; Wei Qin; Marko Z. Vatamaniuk; Changhong Li; Dorothy Zelent; Habiba Najafi; Carol Buettger; Heather W. Collins; Richard D. Carr; Mark A. Magnuson; Franz M. Matschinsky
American Journal of Physiology-endocrinology and Metabolism | 2006
Nicolai M. Doliba; Wei Qin; Marko Z. Vatamaniuk; Carol Buettger; Heather W. Collins; Mark A. Magnuson; Klaus H. Kaestner; David F. Wilson; Richard D. Carr; Franz M. Matschinsky